PMID- 19186072
OWN - NLM
STAT- MEDLINE
DCOM- 20090609
LR  - 20181201
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 70
IP  - 2
DP  - 2009 May
TI  - Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and 
      clinical perspectives.
PG  - 93-102
LID - 10.1016/j.critrevonc.2009.01.001 [doi]
AB  - Tumor hypoxia is a common feature of many cancers. A master regulator of hypoxic 
      response is the transcription factor hypoxia-inducible factor-1 (HIF-1). It 
      functions as a master regulator of oxygen and undergoes conformational changes in 
      response to varying oxygen concentrations. In this paper, we review what has been 
      described about HIF-1: its structure, its regulation and target genes, its role 
      in cancer, and its implication for cancer therapy.
FAU - Otrock, Zaher K
AU  - Otrock ZK
AD  - Department of Pathology and Laboratory Medicine, American University of Beirut 
      Medical Center, Beirut, Lebanon.
FAU - Hatoum, Hassan A
AU  - Hatoum HA
FAU - Awada, Ahmad H
AU  - Awada AH
FAU - Ishak, Rim S
AU  - Ishak RS
FAU - Shamseddine, Ali I
AU  - Shamseddine AI
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090131
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide)
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (Indoles)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Mustard Compounds)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyrroles)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Animals
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Bevacizumab
MH  - Cell Hypoxia
MH  - Enzyme Inhibitors/therapeutic use
MH  - Humans
MH  - Hypoxia-Inducible Factor 1/antagonists & 
      inhibitors/chemistry/genetics/*metabolism
MH  - Indoles/therapeutic use
MH  - Intercellular Signaling Peptides and Proteins/metabolism
MH  - Mustard Compounds/therapeutic use
MH  - Neoplasms/blood supply/*drug therapy
MH  - Neovascularization, Pathologic/*metabolism
MH  - Phenylpropionates/therapeutic use
MH  - Pyrroles/therapeutic use
MH  - Sunitinib
RF  - 115
EDAT- 2009/02/03 09:00
MHDA- 2009/06/10 09:00
CRDT- 2009/02/03 09:00
PHST- 2008/10/03 00:00 [received]
PHST- 2009/01/09 00:00 [revised]
PHST- 2009/01/14 00:00 [accepted]
PHST- 2009/02/03 09:00 [entrez]
PHST- 2009/02/03 09:00 [pubmed]
PHST- 2009/06/10 09:00 [medline]
AID - S1040-8428(09)00003-1 [pii]
AID - 10.1016/j.critrevonc.2009.01.001 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2009 May;70(2):93-102. doi: 
      10.1016/j.critrevonc.2009.01.001. Epub 2009 Jan 31.